Using joint tissue as a marker for pigmented villonodular synovitis
Part of Bones, joints & muscles, Cancer clinical trials.
This study looks at whether tissue from the joint lining (synovium) can be used as a biomarker to help guide treatment for pigmented villonodular synovitis (PVNS), a condition that causes joint swelling and damage. If you have PVNS and are scheduled for treatment, your joint tissue may be collected during your procedure to help doctors better understand the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with localized or diffuse pigmented villonodular synovitis (PVNS), a non-cancerous joint condition.
- You are being referred for treatment for this condition.
- You are not currently taking blood-thinning medication (anticoagulants).
- You do not have a very low platelet count (below 50,000) in your blood test.
- You are not pregnant or breastfeeding, and you are not under legal guardianship or in prison.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects fluid from your joints (synovial fluid) or tissue from joint replacement surgery to look for biomarkers (biological clues) that could help doctors better diagnose bone and joint diseases.
This study looks for biomarkers (clues) in the joint fluid that can help tell whether an artificial joint is infected. It might help doctors diagnose infections faster and more accurately in the future.
This trial studies knee tissue to find better ways to diagnose early osteoarthritis. It may help people who need a knee injection for pain relief.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This study looks at the cells and molecules in the joint tissue of people with arthritis. The goal is to better understand arthritis and potentially improve treatments.
This study looks at how a body signal called IL-23 may drive inflammation in spondyloarthritis (including joints) using samples from your care. It may help researchers identify which body cells and targets are involved, and how treatments could work better for active disease.
Hear when a new Synovitis Villonodular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.